GlassScriptPhysician profile
Yakov Shaulov
NPI 1497243844
$3,343.48
in general payments reported to CMS, 2019-2025
15 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.22 · 2020: $18.58 · 2023: $752 · 2024: $818 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,072 · Travel and Lodging: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,072.11 |
| Travel and Lodging | $231.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,133.79 | 2023-2025 | Qulipta, Ubrelvy |
| Medtronic, INC. | $378.70 | 2023 | Percept PC Brainsense |
| Merz Pharmaceuticals, LLC | $372.79 | 2024-2025 | Inbrija, Xeomin |
| Amneal Pharmaceuticals LLC | $304.08 | 2024-2025 | Crexont |
| Mdd US Operations, LLC | $264.16 | 2024-2025 | Gocovri |
| W. L. Gore & Associates, INC. | $150.00 | 2025 | Gore Cardioform Septal Occluder |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Jardiance |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Symbravo |
| Alnylam Pharmaceuticals INC. | $122.83 | 2023 | Amvuttra |
| Pfizer INC. | $122.19 | 2025 | |
| Acadia Pharmaceuticals INC | $102.52 | 2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $70.63 | 2025 | |
| Revance Therapeutics, INC. | $31.99 | 2025 | Daxxify |
| Ucb, INC. | $21.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yakov Shaulov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.